. Author manuscript; available in PMC: 2009 Oct 14.

Published in final edited form as: Cancer Gene Ther. 2008 Apr 11;15(7):413–448. doi: 10.1038/cgt.2008.15

Table 7.

Evidence for involvement of ERBB3 in gastrointestinal cancers

	References
Colorectal cancers
Variable association of mRNA and protein levels with poor prognosis	320,325–332
Reduced nuclear ERBB3 in colon tumors, especially carcinomas	332
High expression in colorectal cancer cell lines, association with invasiveness	141,333–335
Pancreatic cancers
Consistent upregulation of mRNA and protein and association with poor prognosis	334,336–339
Correlation with radio resistance	340
Gastric cancer
Increased expression in cancers	277,341,342
High expression in gastric cancer cell lines, and secretion of a truncated product	22
NRG activation of both EGFR/ERBB3 and ERBB2/ERBB3 heterodimers; increase in motility	321,343
Reduced differentiation and increased motility in response to NRG	344
Head and neck cancers (oral cavity)
Highly expressed and associated with poor prognosis of oral cancers in most though not all studies	Positive:³⁴⁷–³⁵¹ No link:³⁵²,³⁵³
Correlation of expression with resistance to EGFR inhibitor gefitinib	354
Increase in carcinogen-induced oral carcinomas in rats	357